Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
May 11, 2023 at 04:04 pm EDT
Share
Aytu BioPharma, Inc. reported earnings results for the third quarter and nine months ended March 31, 2023. For the third quarter, the company reported net loss was USD 7.2 million compared to USD 53.29 million a year ago. Basic loss per share from continuing operations was USD 1.93 compared to USD 35.9 a year ago. Diluted loss per share from continuing operations was USD 1.93 compared to USD 35.9 a year ago.
For the nine months, net loss was USD 14.59 million compared to USD 92.69 million a year ago. Basic loss per share from continuing operations was USD 4.71 compared to USD 68.13 a year ago. Diluted loss per share from continuing operations was USD 4.71 compared to USD 68.13 a year ago.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
AYTU BIOPHARMA, INC. 
